These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18498248)

  • 1. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
    Torbett NE; Luna-Moran A; Knight ZA; Houk A; Moasser M; Weiss W; Shokat KM; Stokoe D
    Biochem J; 2008 Oct; 415(1):97-110. PubMed ID: 18498248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
    Jamieson S; Flanagan JU; Kolekar S; Buchanan C; Kendall JD; Lee WJ; Rewcastle GW; Denny WA; Singh R; Dickson J; Baguley BC; Shepherd PR
    Biochem J; 2011 Aug; 438(1):53-62. PubMed ID: 21668414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
    Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
    Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
    [No Abstract]   [Full Text] [Related]  

  • 4. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
    Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
    Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
    Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
    Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
    Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
    Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.
    Höland K; Boller D; Hagel C; Dolski S; Treszl A; Pardo OE; Cwiek P; Salm F; Leni Z; Shepherd PR; Styp-Rekowska B; Djonov V; von Bueren AO; Frei K; Arcaro A
    PLoS One; 2014; 9(4):e94132. PubMed ID: 24718026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
    Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
    Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
    Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
    Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
    Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
    Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M
    Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
    Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
    Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
    Jang K; Kim M; Seo HS; Shin I
    Oncol Rep; 2010 Sep; 24(3):787-93. PubMed ID: 20664988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.
    Juvin V; Malek M; Anderson KE; Dion C; Chessa T; Lecureuil C; Ferguson GJ; Cosulich S; Hawkins PT; Stephens LR
    PLoS One; 2013; 8(10):e75045. PubMed ID: 24124465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting phosphoinositide 3-kinase: moving towards therapy.
    Marone R; Cmiljanovic V; Giese B; Wymann MP
    Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.
    Ni J; Liu Q; Xie S; Carlson C; Von T; Vogel K; Riddle S; Benes C; Eck M; Roberts T; Gray N; Zhao J
    Cancer Discov; 2012 May; 2(5):425-33. PubMed ID: 22588880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.